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Abstract
Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid
leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase
inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior
TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-negative/BCR-ABL1+ CML) received bosutinib 500 mg once
daily (starting dose). As of ≥1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP
CML patients remained on bosutinib. Primary endpoint of cumulative conﬁrmed major cytogenetic response (MCyR) rate by
1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative
complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%,
respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most
common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of
patients had conﬁrmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients
resistant/intolerant to prior TKIs.

Introduction
Additional BYOND Study Investigators are listed below
Acknowledgements.
Supplementary information The online version of this article (https://
doi.org/10.1038/s41375-020-0915-9) contains supplementary
material, which is available to authorized users.

Chronic myeloid leukemia (CML) is a myeloproliferative
neoplasm characterized by the presence of the Philadelphia
chromosome (Ph) [1]. Imatinib was the ﬁrst BCR-ABL1targeting tyrosine kinase inhibitor (TKI) approved for the
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treatment of CML [2, 3]. The 2nd-generation TKIs dasatinib, nilotinib, and bosutinib can be used as ﬁrst-line therapy
alternatives to imatinib for chronic phase (CP) CML [4–6].
However, patients may become resistant or intolerant to
ﬁrst-line TKI treatment [7–10]. Therapy options in the
second-line setting are dasatinib, nilotinib, and bosutinib, or
the 3rd-generation BCR-ABL1 TKI ponatinib [11–14].
TKIs radotinib and asciminib are emerging as treatment
options [9, 15].
Approval of bosutinib for patients with Ph+ CP, accelerated phase (AP), or blast phase (BP) CML previously
treated with ≥1 TKI was based on results from a phase
1/2 study [13, 16]. In patients with imatinib-resistant or
imatinib-intolerant Ph+ CML, and in patients who had
received prior imatinib plus dasatinib and/or nilotinib,
bosutinib 500 mg once daily (QD) demonstrated durable
efﬁcacy and manageable toxicity after longer follow-up
[17–19]. At year 5, 40% of patients resistant/intolerant to
imatinib remained on bosutinib; cumulative major cytogenetic response (MCyR), complete cytogenetic response
(CCyR), and major molecular response (MMR) rates were
60%, 50%, and 42%, respectively [19]. In a 4-year followup of patients receiving bosutinib in the third- or fourth-line
setting, cumulative MCyR and CCyR rates were 40% and
32%, respectively [18]. Across all patients with Ph+ CP
CML in that study, the most common (≥30%) adverse
events (AEs) were diarrhea, nausea, and vomiting [18, 19].
The purpose of the current phase 4 study was to provide
further information on the treatment with bosutinib of
patients with CML resistant/intolerant to prior TKIs or who
were otherwise not appropriate for treatment with other
TKIs. This study also aimed to fulﬁll a post-authorization
commitment to the European Medicines Agency regarding
the efﬁcacy and safety of bosutinib in this patient
population.

Methods
Study design and patients
BYOND (NCT02228382) is an ongoing, single-arm, openlabel, non-randomized phase 4 study of bosutinib in patients
with chronic or advanced Ph+ CML who have failed prior
treatment with TKIs. Eligible patients were adults with a
cytogenetic or qualitative polymerase chain reaction-based
diagnosis of Ph+ and/or BCR-ABL1+ CML (from initial
diagnosis), prior treatment with ≥1 TKI for CML and adequate hepatic/renal function. Any CML phase was permitted, as long as the patient was resistant/intolerant to prior
TKIs. Patients with CP CML and treated with one or two
prior TKIs were required to have Eastern Cooperative
Oncology Group performance status (ECOG PS) 0 or 1;
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those with CP CML after three prior TKIs and with AP/BP
CML could have ECOG PS 0–3. Patients with leptomeningeal leukemia or a known BCR-ABL1 T315I or V299L
mutation were excluded. Additional details on eligibility
criteria are in Supplementary Methods.
Patients received bosutinib at a starting dose of 500 mg
QD. Dose escalation to a maximum of 600 mg QD was
permitted due to unsatisfactory response or signs of disease
progression in the absence of any grade 3/4 or persistent
grade 2 AEs. Dose reduction to 400, 300, or 200 mg QD
due to toxicity/tolerability was permitted (see Supplementary Methods). Patients were to receive bosutinib for up to 4
years from the time of ﬁrst dose, unless disease progression,
unacceptable toxicity, withdrawal of consent, death, or
study discontinuation. Patients who discontinued bosutinib
prior to completing 4 years of therapy were to be followed
for survival until they completed 4 years on study.
The study was approved by institutional review boards
and independent ethics committees at each center. The
study was conducted in accordance with all local legal and
regulatory requirements, as well as the general principles set
forth in the International Ethical Guidelines for Biomedical
Research Involving Human Patients, Guidelines for Good
Clinical Practice and the Declaration of Helsinki. All
patients provided written informed consent.

Endpoints and analyses
The primary endpoints were cumulative conﬁrmed MCyR
(in two consecutive analyses ≥28 days apart) by 1 year
(52 weeks) in patients with Ph+ CP CML treated with one
or two prior TKIs and three prior TKIs, and cumulative
conﬁrmed overall hematologic response (OHR; in two
consecutive analyses ≥28 days apart) by 1 year (52 weeks)
in patients with AP or BP CML. Cumulative conﬁrmed
MCyR was deﬁned as CCyR (0% Ph+ from ≥20 metaphases or <1% ﬂuorescent in situ hybridization [FISH]
positive cells from ≥200 interphase nuclei) or partial cytogenetic response (PCyR; >0%, ≤35% Ph+). To be considered a responder, the patient must have had maintenance
of baseline response for ≥52 weeks for cytogenetic response
or an improvement from baseline. Patients with PCyR at
baseline must have attained CCyR on-treatment to be considered a cytogenetic responder. Patients with at least MMR
and a deeper molecular response (MR) than baseline were
counted as conﬁrmed CCyR. Cumulative conﬁrmed OHR
was deﬁned as complete hematologic response (CHR) or
return to CP.
Key secondary and exploratory endpoints included:
cumulative MCyR (unconﬁrmed); cumulative MMR (BCRABL1 International Scale [IS] ≤ 0.1%), MR4 (BCR-ABL1
IS ≤ 0.01%), and MR4.5 (BCR-ABL1 IS ≤ 0.0032%); BCRABL1 mutational analyses; on-treatment transformation to
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AP or BP CML; overall survival (OS); safety; and patientreported outcome (PRO) measures.
Analyses for molecular, cytogenetic, and hematologic
responses are described in Supplementary Methods. CCyR
was imputed from MMR on a speciﬁc date if there was no
valid cytogenetic assessment. Time to response was deﬁned
as the interval from the date of ﬁrst dose of bosutinib to
initial response. Non-responders were censored at the last
valid assessment date for the respective endpoint. OS was
deﬁned as the interval from the date of ﬁrst dose of bosutinib to the date of death due to any cause. Patients not
known to have died were censored at the last known alive
date. Time to response was estimated using cumulative
incidence, adjusting for the competing risk of treatment
discontinuation without the event; OS was estimated using
the Kaplan–Meier method. Two-sided 95% conﬁdence
interval (CI) for response rate was determined using the
exact binomial method. For Kaplan–Meier's yearly probability estimates, two-sided 95% CI was based on Greenwood’s formula using a log(-log) transformation.
Treatment-emergent AEs (TEAEs), serious AEs, and
laboratory evaluations were assessed up to 28 days after last
dose. Events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events, v4.0. The frequency of selected adverse events of
special interest was analyzed by selecting Medical Dictionary for Regulatory Activities (MedDRA) system organ
class higher level group, higher level and preferred terms
and standardized MedDRA queries to generate TEAE
clusters (see Supplementary Methods).
PROs were assessed using the Functional Assessment of
Cancer Therapy-Leukemia (FACT-Leu) quality-of-life
(QoL) questionnaire (see Supplementary Methods). For
each cohort at each of the timepoints, summary statistics for
the observed values as well as changes from baseline were
estimated. As a supplemental post hoc analysis, a repeated
measures longitudinal model was used to estimate the
relationship between MR (screening to month 12 represented by a log-reduction scale) as a predictor and FACTLeu total score and each domain score as an outcome. The
standardized effect sizes were calculated to determine
strength of effects and allow comparisons across FACT-Leu
domains.
This study did not include any formal sample size
determination and results are descriptive only. Approximately 150 patients with Ph+ CML were to be enrolled,
including ≥45 patients with CP, AP, or BP CML treated in
the fourth-line or later setting. All treated patients with Ph+
CML with a valid baseline efﬁcacy assessment for the
respective endpoint (evaluable population) were included in
the molecular, cytogenetic, and hematologic efﬁcacy analyses. All patients who received ≥1 dose of study drug (full
analysis set) were included in the safety analyses and those
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with Ph+ CP CML were included in the PRO analyses.
Ph+ CP CML patients were also analyzed by resistance or
intolerance to prior TKIs as assessed by the investigator
(Supplementary Methods). Data are from an unlocked trial
database with a cut-off date of September 18, 2018,
≥12 months after last enrolled patient.

Results
Patients and treatment
A total of 163 patients were enrolled between November
20, 2014 and September 18, 2017 across 41 study centers in
eight countries. Of 163 patients who received bosutinib, 156
had Ph+ CP CML, four had Ph+ AP CML, and three had
Ph−/BCR-ABL1+ CP CML. Across Ph+ CP CML cohorts,
51.9% of patients were male and median age was 61.0
years; 29.5%, 39.1%, and 31.4% received bosutinib as
second-, third- and fourth-line TKI therapy, respectively
(Table 1). In all, 53.2% of patients with Ph+ CP CML were
resistant to ≥1 prior TKI and 46.8% were intolerant to all
prior TKIs. Imatinib was the most common prior TKI,
received by 90.4% of patients. All patients with AP CML
were male, with a median age of 40.0 years; two each
received bosutinib as third- and fourth-line TKI therapy. All
patients with Ph− CML were male, with a median age of
63.0 years; two received bosutinib as second-line and one as
third-line TKI therapy.
As of ≥1 year after last enrolled patient (~85% with ≥2year follow-up), 56.4% of patients with Ph+ CP CML
remained on bosutinib: 67.4%, 54.1%, and 49.0% in the
second-, third-, and fourth-line cohorts, respectively
(Fig. 1). In all, 59.0% of TKI-resistant patients and 53.4%
of TKI-intolerant patients remained on bosutinib. The most
common primary reasons for permanent treatment discontinuation were AEs in 39 (25.0%) and insufﬁcient
clinical response in eight (5.1%) patients. Three of four
patients with AP CML discontinued bosutinib due to AE,
insufﬁcient response, or lost to follow-up (n = 1 each). All
three patients with Ph− CP CML discontinued bosutinib
due to AE (n = 2) or death (n = 1).
Median (range) duration of bosutinib treatment was 23.7
(0.2–42.2) months in the Ph+ CP CML cohort: 25.9
(0.9–41.2), 24.2 (0.4–42.2), and 12.3 (0.2–41.9) in the
second-, third-, and fourth-line cohorts, respectively. In the
AP and Ph− CML cohorts, median (range) duration of
bosutinib treatment was 18.0 (1.6–32.3) and 7.2 (3.4–25.8)
months, respectively. Median (range) dose intensity in the
Ph+ CP CML cohort was 313.1 (79.7–560.6) mg/day:
320.1 (98.4–560.6), 309.4 (79.7–500.0), and 308.0
(125.0–500.0) in the second-, third-, and fourth-line cohorts,
respectively. In the AP and Ph− CML cohorts, median
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Table 1 Demographic and
baseline characteristics across
patients with Ph + CP CML.
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Characteristic

Second-line
(n = 46)
Male, n (%)
Age, median (range), years

Total (N = 156)

Line of treatment

23 (50.0)

Third-line
(n = 61)
37 (60.7)

Fourth-line
(n = 49)
21 (42.9)

81 (51.9)

54.0 (19.0–88.0) 65.0 (27.0–85.0) 61.0 (21.0–85.0) 61.0 (19.0–88.0)

Age group, n (%)
<65 years

34 (73.9)

30 (49.2)

32 (65.3)

96 (61.5)

≥65 years

12 (26.1)

31 (50.8)

17 (34.7)

60 (38.5)

0

34 (73.9)

40 (65.6)

32 (65.3)

106 (67.9)

1

12 (26.1)

20 (32.8)

13 (26.5)

45 (28.8)

ECOG PS, n (%)

2
Median (range) duration since
CML diagnosis, years

0
2.2 (0.2–11.4)

1 (1.6)
5.0 (0.3–18.6)

4 (8.2)

5 (3.2)

7.3 (0.7–27.7)

4.7 (0.2–27.7)

Prior TKI, n (%)a
Imatinib

35 (76.1)

57 (93.4)

49 (100)

141 (90.4)

Dasatinib

5 (10.9)

41 (67.2)

49 (100)

95 (60.9)

Nilotinib

6 (13.0)

24 (39.3)

49 (100)

79 (50.6)

Prior interferon alpha, n (%)

2 (4.3)

3 (4.9)

6 (12.2)

Resistant to any prior TKI, n (%)

17 (37.0)

35 (57.4)

31 (63.3)

11 (7.1)
83 (53.2)

Intolerant to all prior TKIs, n (%)

29 (63.0)

26 (42.6)

18 (36.7)

73 (46.8)

Full analysis set.
CML chronic myeloid leukemia, CP chronic phase, ECOG PS Eastern Cooperative Oncology Group
performance status, Ph Philadelphia chromosome, TKI tyrosine kinase inhibitor.
a

In the third-line cohort, 37 (60.7%) of patients received prior imatinib and dasatinib, 20 (32.8%) of patients
received prior imatinib and nilotinib and 4 (6.6%) of patients received prior dasatinib and nilotinib.

(range) dose intensity was 497.9 (346.6–500.0) and 296.2
(81.0–422.8) mg/day, respectively. Median (range) duration
of bosutinib treatment was 23.4 (0.2–42.2) months in TKIresistant and 25.3 (0.4–41.9) months in TKI-intolerant
patients, respectively. Corresponding median (range) dose
intensity was 405.9 (125.0–560.6) and 292.0 (79.7–500.0)
mg/day. At all timepoints, 500 mg QD was the most commonly utilized dosage and >50% of patients with Ph+ CP
CML were receiving 400 or 500 mg QD (Supplementary
Fig. S1).

Efﬁcacy
Of 144 evaluable patients with Ph+ CP CML, the primary
endpoint of cumulative conﬁrmed MCyR rate (95% CI) by 1
year was 75.8% (66.1–83.8%) in those treated with one or
two prior TKIs, and 62.2% (46.5–76.2%) in those previously
treated with three TKIs. In all, 112 (77.8%) patients with
Ph+ CP CML had MCyR at baseline. In the overall Ph+ CP
CML cohort, the cumulative conﬁrmed MCyR rate (95% CI)
by 1 year was 71.5% (63.4–78.7%); 64.6% of patients
achieved a deeper response relative to baseline and 6.9%
maintained their baseline response for ≥1 year. In the four

patients with AP CML, the primary endpoint of cumulative
conﬁrmed OHR rate (95% CI) by 1 year was 75.0%
(19.4–99.4%), as was cumulative conﬁrmed CHR rate.
Cumulative MCyR and CCyR rates, respectively, by 1
year were 83.3 and 80.6% in patients with Ph+ CP CML
(TKI-resistant: 79.2 and 75.3%; TKI-intolerant: 88.1 and
86.6%); cumulative MCyR and CCyR rates by line of
therapy are shown in Table 2. In patients without the
respective baseline response, cumulative MCyR and CCyR
rates, respectively, by 1 year were 59.4 and 63.5% (TKIresistant: 56.5 and 58.8%; TKI-intolerant: 66.7 and 72.2%;
Table 2). Cytogenetic responses were achieved within 1
year with the exception of one TKI-resistant patient who
achieved a CCyR after month 12.
The cumulative MMR rate by 1 year was 70.5% in the
overall Ph+ CP CML cohort (TKI-resistant: 60.5%; TKIintolerant: 80.8%); rates according to line of therapy are
shown in Table 3. In patients without MMR at baseline, the
cumulative MMR rate by 1 year was 58.2% (TKI-resistant:
43.8%; TKI-intolerant: 80.6%). (Table 3). By 1 year,
cumulative MR4 and MR4.5 rates, respectively, were 51.0
and 33.6% (TKI-resistant: 39.5 and 25.0%; TKI-intolerant:
63.0 and 42.5%). In patients without the respective response
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Screened (N = 177)
Excluded (N = 14)
• Screen failure: n = 14
Enrolled (N = 163)

Ph+ CP CML (N = 156)
• FAS: N = 156
• Evaluable molecular: N = 149
• Evaluable cytogenetic: N = 144
• Evaluable hematologic: N = 153

Second-line Ph+ CP CML
(N = 46)

Ph+ AP CML (N = 4)
• FAS: N = 4
• Evaluable molecular: N = 4
• Evaluable cytogenetic: N = 4
• Evaluable hematologic: N = 4

Ph-/BCR-ABL+ CP CML (N = 3)
• FAS: n = 3
• Evaluable molecular: N = 2
• Evaluable cytogenetic: N = 0
• Evaluable hematologic: N = 3

Discontinued (N = 3)
• Adverse events: n = 1
– Related AE: n = 1
• Insufficient clinical response: n = 1
• Lost to follow up: n = 1

Discontinued (N = 3)
• Adverse events: n = 2
– Related AE: n = 1
– Unrelated AE: n = 1
• Death: n = 1

Third-line Ph+ CP CML
(N = 61)

Discontinued (N = 15)
• Adverse events: n = 10
– Related AE: n = 6
– Unrelated AE: n = 4
• Insufficient clinical response: n = 1
• Non-compliance with study treatment: n = 2
• Investigator declined further
participation: n = 1
• Other: n = 1

Fourth-line Ph+ CP CML
(N = 49)

Discontinued (N = 28)
• Adverse events: n = 16
– Related AE: n = 12
– Unrelated AE: n = 4
• Death: n = 1
• Insufficient clinical response: n = 2
• Non-compliance with study treatment: n = 2
• Investigator declined further
participation: n = 1
• Protocol violation: n = 1
• Patient refused further treatment for reason
other than AE: n = 3
• Other: n = 2

Discontinued (N = 25)
• Adverse events: n = 13
– Related AE: n = 12
– Unrelated AE: n = 1
• Insufficient clinical response: n = 5
• Non-compliance with study treatment: n = 1
• Protocol violation: n = 2
• Lost to follow up: n = 1
• Patient refused further treatment for reason
other than AE: n = 2
• Other: n = 1

Fig. 1 Patient disposition. Full analysis set. The 14 participants screened but not enrolled did not meet the eligibility criteria. AE adverse events,
AP accelerated phase, CML chronic myeloid leukemia, CP chronic phase, FAS full analysis set, Ph Philadelphia chromosome.

Table 2 Cumulative cytogenetic response rates by 1 year in patients with Ph + CP CML: total cohort, by line of therapy, and by TKI resistance or
intolerance (overall and excluding patients with the respective baseline response).
Total N = 156

By line of therapy
Second-line n = 46

By TKI resistance or intolerance
Third-line n = 61

Fourth-line n = 49

Resistant n = 83

Intolerant n = 73

67

Cumulative cytogenetic response, % (95% CI)
Evaluable patients, n

144

43

56

45

77

MCyR

83.3 (76.2–89.0)

88.4 (74.9–96.1)

83.9 (71.7–92.4)

77.8 (62.9–88.8)

79.2 (68.5–87.6)

88.1 (77.8–94.7)

CCyR

80.6 (73.1–86.7)

83.7 (69.3–93.2)

83.9 (71.7–92.4)

73.3 (58.1–85.4)

75.3 (64.2–84.4)

86.6 (76.0–93.7)

Cumulative cytogenetic response in patients without the respective baseline response, % (95% CI)
Evaluable patients, n
MCyR
Evaluable patients, n
CCyR

32

10

10

12

23

9

59.4 (40.6–76.3)

80.0 (44.4–97.5)

60.0 (26.2–87.8)

41.7 (15.2–72.3)

56.5 (34.5–76.8)

66.7 (29.9–92.5)

52

16

19

17

34

18

63.5 (49.0–76.4)

75.0 (47.6–92.7)

68.4 (43.4–87.4)

47.1 (23.0–72.2)

58.8 (40.7–75.4)

72.2 (46.5–90.3)

Evaluable cytogenetic population. To be considered a responder, the patient must have maintenance of baseline response while on-treatment or an
improvement from baseline. Patients with MMR or better are counted as CCyR if a valid cytogenetic assessment is not available on a speciﬁc date.
Associated two-sided 95% CI based on the exact method by Clopper–Pearson.
CCyR complete cytogenetic response, CI conﬁdence interval, CML chronic myeloid leukemia, CP chronic phase, MCyR major cytogenetic
response, Ph Philadelphia chromosome, TKI tyrosine kinase inhibitor.
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Table 3 Cumulative molecular response rates by 1 year, by 2 years, and any time on treatment in patients with Ph + CP CML: total cohort, by line
of therapy and by TKI resistance or intolerance (overall and excluding patients with the respective baseline response).
Total N = 156

By line of therapy

By TKI resistance or intolerance

Second-line n = 46

Third-line n = 61

Fourth-line n = 49

Resistant n = 83

Intolerant n = 73

46

55

48

76

73

Cumulative molecular response, % (95% CI)
Evaluable patients, n

149

MMR
By 1 year

70.5 (62.5–77.7)

80.4 (66.1–90.6)

74.5 (61.0–85.3)

56.3 (41.2–70.5)

60.5 (48.6–71.6)

80.8 (69.9–89.1)

By 2 years

71.1 (63.2–78.3)

82.6 (68.6–92.2)

74.5 (61.0–85.3)

56.3 (41.2–70.5)

61.8 (50.0–72.8)

80.8 (69.9–89.1)

Any time on treatment

71.8 (63.9–78.9)

82.6 (68.6–92.2)

76.4 (63.0–86.8)

56.3 (41.2–70.5)

61.8 (50.0–72.8)

82.2 (71.5–90.2)

MR4
By 1 year

51.0 (42.7–59.3)

58.7 (43.2–73.0)

54.5 (40.6–68.0)

39.6 (25.8–54.7)

39.5 (28.4–51.4)

63.0 (50.9–74.0)

By 2 years

55.7 (47.3–63.8)

67.4 (52.0–80.5)

60.0 (45.9–73.0)

39.6 (25.8–54.7)

46.1 (34.5–57.9)

65.8 (53.7–76.5)

Any time on treatment

57.0 (48.7–65.1)

69.6 (54.2–82.3)

61.8 (47.7–74.6)

39.6 (25.8–54.7)

46.1 (34.5–57.9)

68.5 (56.6–78.9)

33.6 (26.0–41.7)

32.6 (19.5–48.0)

36.4 (23.8–50.4)

31.3 (18.7–46.3)

25.0 (15.8–36.3)

42.5 (31.0–54.6)

MR4.5
By 1 year
By 2 years

43.0 (34.9–51.3)

47.8 (32.9–63.1)

45.5 (32.0–59.4)

35.4 (22.2–50.5)

35.5 (24.9–47.3)

50.7 (38.7–62.6)

Any time on treatment

46.3 (38.1–54.7)

56.5 (41.1–71.1)

47.3 (33.7–61.2)

35.4 (22.2–50.5)

36.8 (26.1–48.7)

56.2 (44.1–67.8)

48
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Cumulative molecular response in patients without the respective baseline response, % (95% CI)
Evaluable patients, n

79

25

28

26

MMR
By 1 year

58.2 (46.6–69.2)

72.0 (50.6–87.9)

64.3 (44.1–81.4)

38.5 (20.2–59.4)

43.8 (29.5–58.8)

80.6 (62.5–92.5)

By 2 years

59.5 (47.9–70.4)

76.0 (54.9–90.6)

64.3 (44.1–81.4)

38.5 (20.2–59.4)

45.8 (31.4–60.8)

80.6 (62.5–92.5)

Any time on treatment

59.5 (47.9–70.4)

76.0 (54.9–90.6)

64.3 (44.1–81.4)

38.5 (20.2–59.4)

45.8 (31.4–60.8)

80.6 (62.5–92.5)

112

37

38

37

60

52

Evaluable patients, n
MR4
By 1 year

42.0 (32.7–51.7)

51.4 (34.4–68.1)

44.7 (28.6–61.7)

29.7 (15.9–47.0)

26.7 (16.1–39.7)

59.6 (45.1–73.0)

By 2 years

48.2 (38.7–57.9)

62.2 (44.8–77.5)

52.6 (35.8–69.0)

29.7 (15.9–47.0)

35.0 (23.1–48.4)

63.5 (49.0–76.4)

Any time on treatment
Evaluable patients, n

49.1 (39.5–58.7)

64.9 (47.5–79.8)

52.6 (35.8–69.0)

29.7 (15.9–47.0)

35.0 (23.1–48.4)

65.4 (50.9–78.0)
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42

46

43

72

59

26.7 (19.4–35.2)

26.2 (13.9–42.0)

28.3 (16.0–43.5)

25.6 (13.5–41.2)

20.8 (12.2–32.0)

33.9 (22.1–47.4)

MR4.5
By 1 year
By 2 years

37.4 (29.1–46.3)

42.9 (27.7–59.0)

39.1 (25.1–54.6)

30.2 (17.2–46.1)

31.9 (21.4–44.0)

44.1 (31.2–57.6)

Any time on treatment

40.5 (32.0–49.4)

52.4 (36.4–68.0)

39.1 (25.1–54.6)

30.2 (17.2–46.1)

33.3 (22.7–45.4)

49.2 (35.9–62.5)

Evaluable molecular population. To be considered a responder, the patient must have maintenance of baseline response while on-treatment or an
improvement from baseline. MMR: BCR-ABL1 IS ≤ 0.1%; MR4: BCR-ABL1 IS ≤ 0.01%; MR4.5: BCR-ABL1 IS ≤ 0.0032%. Associated two-sided
95% CI based on the exact method by Clopper–Pearson.
CI conﬁdence interval, CML chronic myeloid leukemia, CP chronic phase, IS international scale, MMR major molecular response, MR molecular
response, Ph Philadelphia chromosome, TKI tyrosine kinase inhibitor.

at baseline, cumulative MR4 and MR4.5 rates were 42.0 and
26.7% (TKI-resistant: 26.7 and 20.8%; TKI-intolerant: 59.6
and 33.9%). At any time, respective cumulative MR4 and
MR4.5 rates were 57.0% and 46.3% and 49.1% and 40.5%
in patients without the respective baseline response.
Cumulative MR4 and MR4.5 rates at any time across therapy
lines and in TKI-resistant and TKI-intolerant patients are
shown in Table 3. Responding patients typically achieved
MMR within 1 year of bosutinib initiation and a deep MR
within 2 years of bosutinib initiation, although a small

proportion of patients achieved MR at later time points
(Fig. 2). Of three patients with Ph−/BCR-ABL1+ CML, one
each had MMR, BCR-ABL1 IS ≤ 1%, and no response.
Eleven patients with Ph+ CP CML had mutations at
baseline; of these, two achieved MR5, one achieved MR4.5,
one achieved MMR, and four achieved CHR as best
response. Molecular responses were observed in patients
with F359I, Y253F, A365V, and E255V mutations (Supplementary Table S1). Of 20 patients with Ph+ CP CML
evaluated for new BCR-ABL1 point mutations, one patient
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1.0

Probability of MMR

0.8

0.6

0.4

0.2

0.0
0
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6

9
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21
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27
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33

36

7/105

6/105

4/106

3/106

2/106

1/106

0/107

18

21

24

27

30

33

36

20/83

18/83

13/83

10/83

7/83

4/84

1/85

18

21

24

27

30

33

36

33/62

26/64

20/65

14/65

9/66

2/69

Months
Number at risk / Cumulative event (n)
Total Ph+ CP CML 149/0
95/42

(b)

35/90

22/98

8/105

7/105

6

9

12

15

1.0

Probability of MR 4

0.8

0.6

0.4

0.2

0.0
0

3

Months
Number at risk / Cumulative event (n)
115/21
Total Ph+ CP CML 149/0

(c)

66/57

47/68

31/76

25/81

6

9

12

15

1.0

Probability of MR 4.5

0.8

0.6

0.4

0.2

0.0
0

3

Months
Number at risk / Cumulative event (n)
Total Ph+ CP CML 149/0
122/13

87/34

69/43

54/50

45/57

37/61

Fig. 2 Cumulative Incidence of Molecular Response in Patients with Ph+ CP CML. (a) MMR, (b) MR4, and (c) MR4.5. CML chronic myeloid
leukemia, CP chronic phase, MMR major molecular response, MR molecular response, Ph Philadelphia chromosome.
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in the third-line cohort with a baseline Y253F mutation had
a newly detectable T315I mutation.
By the cutoff date, no patient with Ph+ CP CML had
progressed to AP/BP on treatment. After a median follow-up
of 30.4 months (range 0.7–44.6), 1- and 2-year
Kaplan–Meier OS rates, respectively, were 98.0% and
96.0%, for patients with Ph+ CP CML (second-line: 100
and 97.7%; third-line: 96.7 and 95.0%; fourth-line: 97.9 and
95.4%; Supplementary Fig. S2A). The respective rates were
97.5 and 94.9% in TKI-resistant and 98.6 and 97.2% in TKIintolerant patients (Supplementary Fig. S2B). After a median
follow-up of 20.6 months (range 1.6–32.3) and 26.5 months
(3.5–41.4) for patients with Ph+ AP CML and Ph− CML,
respectively, OS rates (95% CI) at both 1 year and 2 years
were 100% (100–100%) and 66.7% (5.4–94.5%).

Safety
In the overall patient population (N = 163), 99.4% of
patients had ≥1 any grade TEAE and 73.6% of patients had
≥1 grade 3/4 TEAE. Treatment-emergent serious AEs were
reported in 35.6% of patients. TEAEs led to dose reduction
and temporary discontinuation in 77.3% and 75.5% of
patients, respectively, and 42 (25.8%) discontinued treatment due to AEs. The most common AEs leading to discontinuation (≥2% of patients) were increased alanine
aminotransferase (4.9%) and increased aspartate aminotransferase (2.5%). In TKI-resistant and TKI-intolerant
patients, respectively, rates of any grade TEAEs were
100% and 98.6%, and rates of grade 3/4 TEAEs were
69.9% and 79.5%. The rate of dose reductions due to
TEAEs was 73.5% in TKI-resistant patients and 84.9% in
TKI-intolerant patients; respective rate of temporary discontinuations due to TEAEs was 68.7% and 84.9%. Overall, 21.7% and 28.8% of TKI-resistant and TKI-intolerant
patients, respectively, discontinued treatment due to AEs.
There were no relevant differences in the overall frequency
of TEAEs, grade 3/4 TEAEs, or dose reductions/temporary
discontinuations due to TEAEs across lines of treatment.
The most common TEAEs (>30%) in the overall patient
population were diarrhea (87.7%), nausea (39.9%), and
vomiting (32.5%) (Table 4). However, only two (1.2%),
three (1.8%), and two (1.2%) patients discontinued due to
diarrhea, nausea, and vomiting, respectively. Median
(range) time to ﬁrst TEAE of diarrhea was 2.0 (1–304) days,
and the median (range) duration of diarrhea event (any
grade) was 8.0 (1–715) days. Grade 3/4 TEAEs occurring in
>5% of patients were diarrhea (16.0%), increased alanine
aminotransferase (14.1%), thrombocytopenia (8.0%),
increased lipase (6.7%), and pleural effusion (6.1%).
TEAEs of special interest included cardiac (14.7%), vascular (11.7%), effusion (18.4%), metabolic (8.0%), and
gastrointestinal (91.4%; Table 5).
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Table 4 Summary of TEAEs (all grade TEAEs reported in ≥10% of
patients).
n (%)

Total (N = 163)
All grades

Grades 3/4

Any TEAE

162 (99.4)

120 (73.6)

Diarrhea

143 (87.7)

26 (16.0)

Nausea

65 (39.9)

4 (2.5)

Vomiting

53 (32.5)

6 (3.7)

Abdominal pain

46 (28.2)

7 (4.3)

Headache

45 (27.6)

1 (0.6)

ALT increased

42 (25.8)

23 (14.1)

Fatigue

39 (23.9)

2 (1.2)

Abdominal pain upper

36 (22.1)

2 (1.2)

Dyspnea

35 (21.5)

5 (3.1)

Asthenia

33 (20.2)

4 (2.5)

AST increased

32 (19.6)

7 (4.3)

Cough

30 (18.4)

1 (0.6)

Pyrexia

29 (17.8)

5 (3.1)

Constipation

28 (17.2)

2 (1.2)

Arthralgia

28 (17.2)

1 (0.6)

Pleural effusion

27 (16.6)

10 (6.1)

Back pain

27 (16.6)

4 (2.5)

Anemia

25 (15.3)

7 (4.3)

Rash

25 (15.3)

7 (4.3)

Dizziness

25 (15.3)

0

Blood creatinine increased

24 (14.7)

0

Nasopharyngitis

24 (14.7)

Lipase increased

23 (14.1)

0
11 (6.7)

Myalgia

22 (13.5)

2 (1.2)

Decreased appetite

22 (13.5)

1 (0.6)

Edema peripheral

22 (13.5)

1 (0.6)

Thrombocytopenia

18 (11.0)

13 (8.0)

Pain in extremity

17 (10.4)

2 (1.2)

Pruritus

17 (10.4)

2 (1.2)

Full analysis set. Classiﬁcation of adverse events is based on the
Medical Dictionary for Regulatory Activities (v21.1).
ALT alanine aminotransferase, AST aspartate aminotransferase, CML
chronic myeloid leukemia, TEAE treatment-emergent adverse event.

There were 12 deaths, seven of which occurred within
28 days of last dose (six due to AEs not related to bosutinib
and one due to CML, as determined by the investigator)
and ﬁve deaths occurred beyond 28 days of last dose (four
due to AEs not related to bosutinib and one due to an
unknown cause, as determined by the investigator). AEs
resulting in death were: acute kidney injury, respiratory
insufﬁciency due to aspiration, cerebral tumor, chronic
briden-ileus, hemorrhagic shock, lymphoma, metastatic
lung cancer, multiorgan failure, prostate adenocarcinoma,
and sepsis.
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Table 5 TEAEs of special interest.
n (%)
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Table 5 (continued)
Total (N = 163)

Cardiac TEAEs

n (%)
Hypercholesterolemia

Total (N = 163)
3 (1.8)

Any TEAE

24 (14.7)

Hypertriglyceridemia

3 (1.8)

Cardiac disorders

23 (14.1)

Hyperlipidemia

1 (0.6)

Cardiac failure

6 (3.7)

Atrial ﬁbrillation

5 (3.1)

Any TEAE

149 (91.4)

Tachycardia

3 (1.8)

Diarrhea

143 (87.7)

Arrhythmia

2 (1.2)

Abdominal pain

Bradycardia

2 (1.2)

Nausea

65 (39.9)

Cardiac failure congestive

2 (1.2)

Vomiting

53 (32.5)

Atrial ﬂutter

1 (0.6)

Constipation

28 (17.2)

Atrioventricular block complete

1 (0.6)

Bundle branch block right

1 (0.6)

Cardiac failure acute

1 (0.6)

Cardiac ﬂutter

1 (0.6)

Cardiogenic shock

1 (0.6)

Extrasystoles

1 (0.6)

Sinus bradycardia

1 (0.6)

Investigations
Electrocardiogram QT interval
prolonged

1 (0.6)
1 (0.6)

Vascular TEAEs
Any TEAE
Cardiovascular

19 (11.7)
5 (3.1)

Angina pectoris

2 (1.2)

Angina unstable

1 (0.6)

Coronary artery occlusion

1 (0.6)

Myocardial ischemia

1 (0.6)

Cerebrovascular

5 (3.1)

Cerebrovascular accident

2 (1.2)

Transient ischemic attack

2 (1.2)

Carotid artery stenosis
Peripheral vascular

1 (0.6)
10 (6.1)

Peripheral arterial occlusive disease

3 (1.8)

Peripheral ischemia

2 (1.2)

Aortic stenosis

1 (0.6)

Arterial rupture

1 (0.6)

Intermittent claudication

1 (0.6)

Peripheral coldness

1 (0.6)

Vascular pain

1 (0.6)

Effusion TEAEs
Any TEAE
Pleural effusion
Pericardial effusion

Gastrointestinal TEAEs

67 (41.1)

Full analysis set. Classiﬁcation of adverse events is based on the
Medical Dictionary for Regulatory Activities (v21.1). See Supp.
Methods for adverse events of special interest cluster deﬁnitions.
Totals for the number of patients at a higher level are not necessarily
the sum of those at the lower levels since a patient may report two or
more different TEAEs within the higher level category.
TEAE treatment-emergent adverse events.

PROs
At baseline, total FACT-Leu scores were similar (<5%
difference) between the second- and third-line cohorts;
slightly lower scores were reported in the fourth-line cohort
at baseline (Fig. 3 and Supplementary Table S2). Total
FACT-Leu scores were maintained from baseline in all
cohorts following 12 months of bosutinib treatment (Fig. 3);
additionally, at month 12, no mean change in any individual
FACT-Leu domain score from baseline met the MID,
indicating preservation of health-related QoL (HRQoL)
(Supplementary Fig. S3; Fig. 3). Within these MIDs,
FACT-Leu scores increased slightly from baseline to month
12 in the second-line cohort and (except for emotional wellbeing) decreased slightly in the third-line cohort; positive
versus negative changes were less consistent in the fourthline cohort. The effect of MR on HRQoL was variable. For
patients who achieved MR5, the leukemia-speciﬁc domain
showed the greatest improvement, with a large effect size,
followed by the emotional well-being domain and TOI
FACT-Leu, with medium effect sizes; the social well-being
domain was the only domain to demonstrate a beyondtrivial reduction in HRQoL, with a medium effect size
(Supplementary Fig. S4).

30 (18.4)
27 (16.6)
8 (4.9)

Discussion

Metabolic TEAEs
Any TEAE

13 (8.0)

Hyperglycemia

5 (3.1)

Diabetes mellitus

4 (2.5)

Overall, data from the phase 4 BYOND study conﬁrm the
efﬁcacy ﬁndings from the phase 1/2 study of bosutinib in the
second-, third- and fourth-line settings [13, 16–20]. High
rates of cytogenetic and molecular responses were observed
across patients with Ph+ CP CML treated with bosutinib,
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FACT-Leu Total Score

135

120
CP2L
CP3L
CP4L
Total Ph+ CP CML
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Baseline

3
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CP3L
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45

44

41

CP4L

44

36

36

29

24

Total Ph+ CP CML

14 6

13 4

118

1 06

98

Fig. 3 Observed mean (SE) FACT-Leu values over 12 months of
bosutinib treatment. CML chronic myeloid leukemia, CP chronic
phase, CP2L second-line, CP3L third-line, CP4L fourth-line, FACT-

Leu functional assessment of cancer therapy–leukemia, Ph Philadelphia chromosome, SE Standard error.

including a large proportion of patients who achieved deep
MR. The majority of patients achieved deeper responses
relative to baseline with bosutinib, even though most patients
entered the study with at least MCyR from prior treatment.
These high response rates were seen in TKI-resistant and
TKI-intolerant patients and across treatment lines. Although
patients with a more resistant phenotype showed lower
response rates compared with TKI-intolerant patients,
responses were also seen in patients with resistance to imatinib or the 2nd-generation TKIs dasatinib and nilotinib.
Data in patients with CML resistant/intolerant to prior
TKIs were also reported in studies of nilotinib, dasatinib,
and ponatinib [11, 14, 21]. In a phase 2 study of second-line
nilotinib 400 mg twice daily in imatinib-resistant/intolerant
patients (N = 321), MCyR, CCyR, and MMR rates at any
time on treatment were 59%, 44%, and 28%, respectively,
after a minimum follow-up of 24 months [21]. In a phase
3 study of second-line dasatinib (multiple doses) in imatinib-resistant/intolerant patients (N = 670), MCyR, CCyR
and MMR rates by 24 months were 61–63%, 50–54%, and
37–38%, respectively [11]. In the present study, second-line
bosutinib yielded MCyR, CCyR, and MMR rates (both by
24 months and at any time) of 80.0%, 81.3%, and 76.0%,
respectively, in patients without the respective baseline
response. For bosutinib, achieved rates are used for the
purpose of comparisons with the nilotinib and dasatinib
studies due to the higher proportion of patients with baseline MCyR enrolled in BYOND: 77.8% versus 11% and
14–20% for nilotinib and dasatinib, respectively
[11, 21, 22]. In the present study, response rates were higher
in patients treated with fewer previous TKIs; however,

response was also seen in heavily pretreated patients: 47.1%
and 38.5% of patients (without the respective baseline
response) treated with bosutinib fourth-line therapy
achieved CCyR and MMR, respectively, by 1 year. These
data are comparable to those reported in a phase 2 study of
ponatinib 45 mg QD in heavily pretreated patients with CP
CML without the T315I mutation (N = 203); after a median
follow-up of 15 months, MCyR, CCyR, and MMR rates by
12 months were 51%, 40%, and 27%, respectively [14]. In
summary, the current data for bosutinib from BYOND, with
a median follow-up of 30.4 months, showed comparable
cytogenetic and molecular response rates to those reported
with nilotinib, dasatinib, or ponatinib treatment.
Overall, AEs with bosutinib were manageable. The
reported AEs were consistent with the known safety proﬁle
of bosutinib and no new safety issues were identiﬁed
[6, 17–20, 23–27]. Patients intolerant to previous therapies
had a slightly higher incidence of grade 3/4 TEAEs and
required more frequent dose adjustments to manage AEs
than TKI-resistant patients. Nevertheless, most patients
intolerant to previous TKIs, including patients intolerant to
all prior TKIs, were able to remain on treatment with
bosutinib (median treatment duration, 25.3 months). The
overall discontinuation rate due to AEs was consistent with
the previous phase 1/2 study, despite approximately half of
patients being intolerant to all prior TKI therapy, which
indicates that, in general, AEs were manageable with dose
reductions and temporary discontinuations. Despite a high
incidence of diarrhea, which is usually transient and often
improves with dietary changes and the administration of
supportive care, bosutinib discontinuation due to this AE
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was low [28]. In patients who have an increase in transaminases, it is advisable to avoid other hepatotoxic drugs and
excess alcohol consumption, and monitor liver enzymes
more frequently; dose modiﬁcations and/or discontinuation
may be required in more severe cases [29].
As with imatinib, patients treated with dasatinib or
nilotinib may eventually develop resistance to treatment. In
addition, some patients may be unable to continue treatment
with dasatinib, nilotinib, or ponatinib due to intolerance, or
the safety proﬁles of these agents may preclude their use in
patients with certain comorbidities. Safety comparisons
across TKI studies are limited; however, the varying “off
target” effects of bosutinib, nilotinib, dasatinib, and ponatinib are reﬂected in the safety of these agents, with each
BCR-ABL1 TKI showing a distinct toxicity proﬁle.
Vascular AEs have been described mainly with nilotinib
and ponatinib. Metabolic AEs, potentially contributing to
vascular toxicity, are also frequently reported with nilotinib
[14, 21, 30]. The European LeukemiaNet (ELN) recommendations, therefore, state that nilotinib is contraindicated
in patients with a history of coronary heart disease, cerebrovascular accidents, or peripheral arterio-occlusive disease
and that previous or concomitant arteriovascular disease is a
contraindication to ponatinib in second- or third-line treatment. Pulmonary toxicities, such as pleural effusion and
more rarely pulmonary arterial hypertension, have been
primarily associated with dasatinib treatment [11, 31–33],
and the ELN panel recommended to avoid the use of dasatinib in patients with respiratory failure and previous or
concomitant pleuro-pulmonary or pericardial disease. While
the incidence of these speciﬁc AEs with bosutinib in
BYOND was higher than previously reported
[13, 16, 34, 35], the heavily pretreated nature of the patients
might have contributed to this. ELN recommendations state
that no relevant comorbidities or contraindications have been
identiﬁed for bosutinib [15], and bosutinib is a treatment
option for patients with pulmonary or cardiovascular
comorbidities, diabetes mellitus, or hyperglycemia due to the
lower risk of these types of events [36]. Therefore, bosutinib
is an appropriate treatment option for patients resistant or
intolerant to prior TKIs, including in patients who have
previously received treatment with a 2nd-generation TKI
and in those who present with multiple comorbidities.
HRQoL was maintained from baseline in patients with
CP CML following 12 months of bosutinib treatment.
Changes from baseline in patient-reported outcomes measures at month 12 were comparable to those observed in
previously treated patients in the initial phase 1/2 study of
bosutinib, wherein long-term efﬁcacy and HRQoL stability
were reported [19, 37, 38]. In addition, FACT-G scores in
the current study were consistent with those previously
reported for bosutinib in newly diagnosed patients with
CML, in the general population, as well as in patients with
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various cancers [39–43]. Maintenance of HRQoL is
important for patients with CP CML who potentially will
receive lifelong TKI treatment, and PRO results from this
phase 4 study suggest bosutinib is a treatment option with
manageable AEs, providing further support for its use in
patients with CP CML resistant/intolerant to prior TKIs.
The impact of clinical improvement on different dimensions
of HRQoL was variable; for the majority of domains, a
deeper MR was associated with better HRQoL.
In summary, high rates of cytogenetic and molecular
responses, including a large proportion of patients who
achieved MR4 and MR4.5, were observed with bosutinib
treatment. AEs that occurred with bosutinib were manageable [28, 29], further evidenced by maintenance of HRQoL,
and the reported AEs were consistent with the known safety
proﬁle of bosutinib. The results from this phase 4 study
further conﬁrm the use of bosutinib for patients with CML
resistant/intolerant to prior TKIs across all treatment lines.
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